SOD1 and in situ carcinoma: The correlation of miR-497 expression with NIHSS score, MDA, and SOD identified in the present study can further confirm that miR-497 interferes with CIS progression, suggesting that monitoring miR-497 levels in CIS patients can help clinicians to judge patients’ condition in the future.